Protalix BioTherapeutics (PLX) Misses Q2 EPS by 17c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.82 +2.55%
EPS Growth %: -266.7%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -266.7%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.25), $0.17 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $6.43 million versus the consensus estimate of $8.3 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- UBS Reiterates Buy Rating on Option Care Health (OPCH) Following Check-in Call Ahead of Quiet Period
- MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
